Although there are no treatment guidelines for LADA or SPIDDM, the consensus statement by an international expert panel [12] and the report by the Japan Diabetes Society that presents the diagnostic criteria for SPIDDM [2] recommend that, in cases where endogenous insulin secretion is maintained, a treatment plan should be formulated in accordance with the guidelines for type 2 diabetes, with the exception of the use of sulfonylurea agents. Here, INS is linked to type 2 diabetes mellitus.